Corbus Pharmaceuticals (CRBP) KOL event summary

Introduction and agenda

• Early morning session held adjacent to ASCO, focused on oropharyngeal cancer and new therapeutic strategies.

• Panel included leading oncologists with experience in head and neck cancer clinical trials.

• Agenda included epidemiology, patient selection, therapeutic landscape, and Q&A.

KOL background and credentials

• Dr. Ari Rosenberg: Associate Professor, University of Chicago, specializes in novel therapies for head and neck and thyroid cancers, recognized in 40 Under 40 in Cancer.

• Dr. Glenn Hanna: Director, Center for Cancer Therapeutic Innovation, Dana-Farber, focuses on precision medicine and biomarker discovery.

• Dr. Cesar Perez Batista: Director, Drug Development Unit, Sarah Cannon Research Institute, leads early phase trials in solid tumors and head and neck cancer.

Market insights and analysis

• Oropharyngeal squamous cell carcinoma is increasingly HPV-associated, especially in the U.S. and Western Europe.

• HPV vaccination rates remain low, so incidence of HPV-related oropharyngeal cancer will rise for decades.

• Geographic and demographic differences affect HPV prevalence and patient profiles.

• Estimated 7,500–10,000 recurrent/metastatic oropharyngeal patients annually in the U.S., with numbers rising.

• Motivated, fit, and younger HPV-positive patients are more likely to seek and tolerate new therapies.